Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Conclusion
After adjusting for patient population differences, nivolumab + ipilimumab had a statistically significant OS benefit over BRAF + MEK inhibitors. For both OS and PFS, nivolumab + ipilimumab demonstrated a significant benefit in analyses starting at 12 months, indicating that immunotherapy has a more durable benefit than the comparator targeted therapies. Ongoing randomized studies (NCT02224781; NCT02631447) comparing the outcomes of patients initiating treatment with nivolumab + ipilimumab or BRAF + MEK inhibitors will address the issue of confounding by subsequent treatment and are needed to validate these results (Atkins et al. 2019)
…